Karyopharm Therapeutics Inc.
KPTI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001503802
In the last 90 days, Karyopharm Therapeutics Inc. insiders filed 0 open-market purchases and 2 sales; 96 institutions reported holding it in 13F filings for Q2 2026, worth $213.5M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.38K in total
- 2
- 13F holdersQ2 2026, +19 vs. previous quarter
- 96
- 13F valueReported value at the end of Q2 2026
- $213.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding KPTI, Q2 2026
No superinvestor reported holding KPTI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Karyopharm Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 (view filing)4:57 PM ET | Sep 1 | 1 day | Abate KristinChief Accounting Officer | SSale | −19 | $2.02 | −$38.38 | −0.1%23.8K after | |
| Jul 30, 2026 (view filing)4:42 PM ET | Jul 28 | 2 days | Poulton StuartEVP, Chief Development Officer | SSale | −189 | $7.10 | −$1.34K | −0.2%94.6K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Poulton StuartEVP, Chief Development Officer | SSale | −403 | $9.50 | −$3.83K | −0.4%94.8K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Rangwala ReshmaEVP & Chief Medical Officer | SSale | −408 | $9.50 | −$3.88K | −0.7%56.8K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Cheng Sohanya RoshanEVP & Chief Commercial Officer | SSale | −324 | $9.50 | −$3.08K | −0.3%107.9K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Abate KristinChief Accounting Officer | SSale | −53 | $9.50 | −$503.5 | −0.2%23.8K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Paulson Richard A.President and CEO | SSale | −2.20K | $9.50 | −$20.9K | −0.8%269.7K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Mano MichaelEVP, CLO&Secretary | SSale | −266 | $9.50 | −$2.53K | −0.3%94.4K after | |
| Apr 22, 2026 (view filing) | Apr 21 | 1 day | Rangwala ReshmaEVP & Chief Medical Officer | SSale | −449 | $8.94 | −$4.01K | −0.8%56.3K after | |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Abate KristinChief Accounting Officer | SSale | −559 | $9.41 | −$5.26K | −2.5%22.1K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Karyopharm Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 1,917,354 | $18.7M | 0.16% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,521,322 | $14.9M | 0.02% | −285,000−15.8% | Reduced |
| Acorn Capital Advisors, LLC | 1,518,113 | $14.8M | 4.05% | +1,230,287+427.4% | Added |
| Goldman Sachs Group Inc | 1,424,658 | $13.9M | 0.00% | +477,079+50.3% | Added |
| BlackRock, Inc. | 1,418,799 | $13.9M | 0.00% | +1,173,900+479.3% | Added |
| Kalehua Capital Management LLC | 1,371,288 | $13.4M | 4.27% | +1,371,288 | New |
| Vanguard Capital Management LLC | 958,979 | $9.37M | 0.00% | +219,234+29.6% | Added |
| Catalio Capital Management, LP | 940,855 | $9.19M | 1.73% | +43,146+4.8% | Added |
| Avidity Partners Management LP | 924,487 | $9.03M | 1.45% | −2,995−0.3% | Reduced |
| T. Rowe Price Investment Management, Inc. | 786,309 | $7.68M | 0.01% | −755,781−49.0% | Reduced |